3 results
Approved WMORecruiting
Primary: The primary objective of the Double-blind Acute Phase of the study is to assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate UC.The primary…
Approved WMOCompleted
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months
Approved WMOPending
To compare the efficacy of patritumab deruxtecan versus platinumbased chemotherapy, as measured by progression-free survival (PFS), insubjects with metastatic or locally advanced nonsquamous non-small cell lung cancer (NSCLC) with an EGFR-activating…